MRNA
Moderna, Inc.
Key Financials
Operating Income
$-3074000000
↑ 22.1%
Net Income
$-2822000000
↑ 20.8%
Revenue
$1.9B
↓ 39.9%
Total Assets
$12.3B
↓ 12.8%
EPS (Diluted)
$-7.26
↑ 21.8%
Shareholders' Equity
$8.7B
↓ 20.6%
Total Liabilities
$3.7B
↑ 13.8%
Long-term Debt
$590.0M
↑ Infinity%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/18/2026 | View on SEC |
| 144 | 5/15/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MRNA |
| Company Name | Moderna, Inc. |
| CIK | 1682852 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6177146500 |